N@N

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), Down By 5.50% ($0.42) From $7.640 After BUYINS.NET Report Predicted Weakness After Ea

^{Published on 2012-05-02 05:41:05 - WOPRAI}
 

May 2, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, April 30th 2012 stating that NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=nbix&id=269399

At the time this story was written, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is Down By 5.50% ($0.42) From $7.640 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders. Its products in clinical development include Elagolix, a phase II product for endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for cardiovascular diseases; CRF1 Antagonist, a phase I product for treating mood disorders and irritable bowel syndrome; Vesicular Monoamine Transporter 2 Inhibitor, a phase I product for movement disorders and schizophrenia; and Elagolix, a phase I product for uterine fibroids, and mens and womens health. The companys research programs comprise Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic Drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. Its product pipeline also includes Indiplon 5mg and 10mg capsules, the FDA deemed approvable products, for the treatment of insomnia. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott Laboratories to develop and commercialize elagolix for the treatment of endometriosis-related pain; and Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net